Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of the current trial is to explore whether the standard treatment with radiotherapy and temozolomide affect the tumor vasculature in patients with high-grade astrocytomas. If vascular effects are identified, future clinical trials can be proposed wherein anti-angiogenic agents are added to increase patient survival.
Full description
Today's standard treatment with radiotherapy and temozolomide yields a life expectancy of 1.5-3 years in patients with high-grade astrocytomas. Thus, there is a need for further therapeutic improvements in this patient population. The purpose of the current trial is to explore whether radiotherapy and temozolomide affect the tumor vasculature in patients with high-grade astrocytomas. If vascular effects are identified, future clinical trials can be proposed wherein anti-angiogenic agents are added to increase patient survival. Additionally, stem cells within malignant brain tumors is an important new area of research in this patient population, and investigations herein could contribute to identify new predictive markers and therapeutic targets.
Primary objective: To assess the vascular perfusion and permeability characteristics of high-grade astrocytomas (anaplastic astrocytoma and glioblastoma multiforme) using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients receiving radiotherapy and temozolomide. Furthermore to assess whether therapy-induced changes in tumor perfusion is correlated with progression-free survival.
Secondary objectives:
Analyze circulating endothelial cells in the blood by flow cytometry to explore whether these cells can be used as an indirect estimate of angiogenesis in high-grade astrocytomas
Analyze tumor specimens from patients that have had their gliomas debulked before commencing therapy
Assess progression-free survival of all patients included in the study, in order to correlate the survival data with the above tissue sampling results.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically confirmed primary high-grade astrocytoma, i.e. anaplastic astrocytoma or glioblastoma multiforme.
Have a WHO performance status 0-2 and be able to undergo outpatient treatment.
Age ≥18 years.
No pregnant or lactating patients can be included.
Patients must have radiographically documented measurable disease postoperatively. At least one tumor lesion must be unidimensionally measurable as follows:
All diagnostic radiology studies must be performed within 28 days prior to registration.
Absence of conditions making MRI scans impossible;
Patients who are receiving corticosteroids have to receive stable or decreasing doses for at least 14 days before entering the trial.
No prior chemotherapy for high-grade astrocytoma
Absence of opportunistic infections making temozolomide contraindicated.
Minimum required laboratory data:
Hematology:
Biochemistry:
Adequate cognitive function in order to give informed consent.
Absence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Before patient registration/randomization, written informed consent must be given according to national and local regulations.
Exclusion criteria
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal